AKAlwin Krämer

Alwin Krämer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alwin Krämer has a total of 435 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chromosomal instability does not correlate with metastatic potential in human cancer cell lines

    by Greta Mühlmeier, Carolin Feldmann, Timothy Wohlfromm, Bianca N. Kraft, Alwin Krämer

    Purpose: Chromosomal instability (CIN) is a hallmark of cancer that drives tumor evolution. Recent studies suggest that CIN contributes to cancer cell dissemination and metastasis formation. Here, we assessed this relationship in a panel of human cancer cell lines. Methods: Single nucleotide polymorphism (SNP)-based allele-specific copy number analysis was used to determine the weighted genome instability index (wGII) as a measure of CIN in 24 cancer cell lines. Immunofluorescence microscopy was performed to assess micronucleus (MN) formation, cGAS activity, RelB activity, and mitotic chromosome missegregation. Western blotting was employed to analyze for epithelial to mesenchymal transition (EMT). Results: We established a comprehensive panel of 24 cancer cell lines across four tumor entities (colorectal, lung, pancreatic, and prostate cancer) with a wide metastatic potential spectrum to systematically investigate the role of CIN in metastasis. Although CIN and whole-genome doubling (WGD) were highly prevalent, the wGII did not correlate with mitotic chromosome missegregation rates, MN formation, cGAS–STING signaling, or metastatic potential score of the analyzed cell line panel. Furthermore, neither activation of non-canonical NF-κB signaling nor our EMT-marker based score was associated with increased metastatic potential, indicating that these parameters do not predict metastatic potential. Conclusion: Our study demonstrates that commonly used parameters of genomic instability and EMT do not correlate with the metastatic potential of well-established human cancer cell lines. Improved methods for the reliable assessment of ongoing CIN in tumor cells and three-dimensional cell culture models might be utilized to further analyze the impact of CIN on tumor invasion and metastasis.

  • Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study

    by Alwin Krämer, Tilmann Bochtler, Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A. Pazo-Cid, Ferran Losa, Debbie G.J. Robbrecht, Jiří Tomášek, et al.

    CUPISCO (ClinicalTrials.gov identifier: NCT03498521 ) demonstrated longer progression-free survival (PFS) with comprehensive genomic profiling (CGP) and subsequent molecularly guided therapies (MGTs), versus standard platinum-based chemotherapy, in patients with previously untreated, unfavorable cancer of unknown primary (CUP) who reached disease control after induction chemotherapy (three cycles). We report efficacy and safety after >1 year of additional follow-up. Eligible patients were randomly assigned (3:1) to MGT (investigator-chosen after discussion in a molecular tumor board) or three further cycles of chemotherapy. The primary end point was PFS. Secondary end points included overall survival (OS) and safety. At data cutoff (December 6, 2024), 436 patients were randomly assigned (326 to MGT; 110 to chemotherapy). Median follow-up was 37.0 months (range, 0.0-67.8). Updated median PFS was 6.1 months (95% CI, 4.7 to 6.5) with MGT and 4.4 months (95% CI, 4.2 to 6.4) with chemotherapy (hazard ratio [HR], 0.75 [95% CI, 0.59 to 0.95]; P = .017); median OS was 15.2 months (95% CI, 13.9 to 18.4) and 12.8 months (95% CI, 9.8 to 15.4), respectively (HR, 0.79 [95% CI, 0.61 to 1.02]; P = .0689). No new safety signals were identified. These updated results aligned with the primary analysis, demonstrating the benefit of CGP with subsequent MGT and highlighting the importance of incorporating CGP at initial diagnosis to guide treatment decisions for patients with unfavorable CUP.


  • Top Cited Papers

    Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

    by Uwe Platzbecker, Lionel Adès, Pau Montesinos, Emanuele Ammatuna, Pierre Fenaux, Claudia Baldus, Massimo Bernardi, Céline Berthon, Monica Bocchia, Caroline Bonmati, et al.

    PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140 ). METHODS: Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m 2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m 2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m 2 twice daily and idarubicin 12 mg/m 2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS: As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients ( P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events ( P < .01). CONCLUSION: The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.


  • Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment

    by Maria Pouyiourou, Tilmann Bochtler, Chantal Pauli, Holger Moch, Alexander Brobeil, Klaus Pantel, Albrecht Stenzinger, Alwin Krämer

    Cancer of unknown primary (CUP) is a metastatic malignancy for which a primary site of origin cannot be identified despite a thorough and standardized diagnostic work-up, and accounts for 1-3% of all malignancies. An unfavourable subgroup of CUP has a poor prognosis, with a median overall survival of <1 year when treated with current standard-of-care platinum-based chemotherapy. Virtually no progress in elucidating the disease biology and improving outcomes for patients with unfavourable CUP has been made over the past several decades, including a failure of initial randomized clinical trials to demonstrate the superiority of tissue-of-origin (ToO) identification by gene-expression profiling and subsequent primary-site-directed treatment over standard chemotherapy. However, large-cohort randomized trials have now shown that molecularly guided therapy improves outcomes for patients with CUP harbouring an actionable target, both in a tissue-agnostic as well as a primary tumour site-specific context. Moreover, data from non-randomized phase II trials suggest that immunotherapy using immune-checkpoint inhibitors can be beneficial even in patients with CUP that has relapsed after, or is refractory to, standard chemotherapy. In addition, a plethora of refined and novel strategies, including DNA and RNA sequencing, DNA-methylation profiling, circulating tumour DNA analysis, and artificial intelligence-based pathology, have been leveraged to facilitate ToO identification. In light of these developments, we review current ToO methodologies and compare the evidence supporting the use of a primary tumour site-guided approach versus a histology-agnostic approach to the management of CUP. We also discuss whether CUP can be viewed as a model disease for the development of histology-agnostic precision oncology treatment strategies.


  • 56/w mit Rückenschmerzen und Nachtschweiß

    by Maria Pouyiourou, Tilmann Bochtler, Alwin Krämer

  • Open Access

    STIL overexpression shortens lifespan and reduces tumor formation in mice

    by Amira-Talaat Moussa, Marco R Cosenza, Timothy Wohlfromm, Katharina Brobeil, Anthony Hill, Annarita Patrizi, Karin Müller-Decker, Tim Holland-Letz, Anna Jauch, Bianca Kraft, et al.

    Centrosomes are the major microtubule organizing centers of animal cells. Supernumerary centrosomes are a common feature of human tumors and associated with karyotype abnormalities and aggressive disease, but whether they are cause or consequence of cancer remains controversial. Here, we analyzed the consequences of centrosome amplification by generating transgenic mice in which centrosome numbers can be increased by overexpression of the structural centrosome protein STIL. We show that STIL overexpression induces centrosome amplification and aneuploidy, leading to senescence, apoptosis, and impaired proliferation in mouse embryonic fibroblasts, and microcephaly with increased perinatal lethality and shortened lifespan in mice. Importantly, both overall tumor formation in mice with constitutive, global STIL overexpression and chemical skin carcinogenesis in animals with inducible, skin-specific STIL overexpression were reduced, an effect that was not rescued by concomitant interference with p53 function. These results suggest that supernumerary centrosomes impair proliferation in vitro as well as in vivo, resulting in reduced lifespan and delayed spontaneous as well as carcinogen-induced tumor formation.


  • Open Access

    Cancer of unknown primary derived from regressed breast cancer

    by Maria Pouyiourou, Theresa Mokry, Maximilian Feszler, Andrea Teifke, Andreas Kreft, Alwin Krämer

  • Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary

    by Maria Pouyiourou, Tilmann Bochtler, Cornelia Coith, Harriet Wikman, Bianca Kraft, Thomas Hielscher, Albrecht Stenzinger, Sabine Riethdorf, Klaus Pantel, Alwin Krämer

    Cancer of unknown primary (CUP) is defined as a primary metastatic malignancy, in which the primary tumor remains elusive in spite of a comprehensive diagnostic workup. The frequency and prognostic value of circulating tumor cells (CTCs), which are considered to be the source of metastasis, has not yet been systematically evaluated in CUP. A total of 110 patients with a confirmed diagnosis of CUP according to the European Society for Medical Oncology (ESMO) guidelines, who presented to our clinic between July 2021 and May 2023, provided blood samples for CTC quantification using CellSearch methodology. CTC counts were correlated with demographic, clinical, and molecular data generated by comprehensive genomic profiling of tumor tissue. CTCs were detected in 26% of all patients at initial presentation to our department. The highest CTC frequency was observed among patients with unfavorable CUP (35.5%), while patients with single-site/oligometastatic CUP harbored the lowest CTC frequency (11.4%). No statistically significant association between CTC positivity and the number of affected organs (P = 0.478) or disease burden (P = 0.120) was found. High CTC levels (≥5 CTCs/7.5 mL; 12/95 analyzed patients) predicted for adverse overall survival compared to negative or low CTC counts (6-months overall survival rate 90% vs 32%, log-rank P < 0.001; HR 5.43; 95% CI 2.23–13.2). CTC dynamics were also prognostic for overall survival by landmark analysis (log-rank P < 0.001, HR 10.2, 95% CI 1.95–52.9). CTC frequency is a strong, independent predictor of survival in patients with CUP. CTC quantification provides a useful prognostic tool in the management of these patients.


  • Open Access

    STIL overexpression shortens lifespan and reduces tumor formation in mice

    by Amira-Talaat Moussa, Marco R. Cosenza, Timothy Wohlfromm, Katharina Brobeil, Anthony Hill, Annarita Patrizi, Karin Müller-Decker, Tim Holland-Letz, Anna Jauch, Bianca Kraft, et al.

    Centrosomes are the major microtubule organizing centers of animal cells. Supernumerary centrosomes are a common feature of human tumors and associated with karyotype abnormalities and aggressive disease, but whether they are cause or consequence of cancer remains controversial. Here, we analyzed the consequences of centrosome amplification by generating transgenic mice in which centrosome numbers can be increased by overexpression of the structural centrosome protein STIL. We show that STIL overexpression induces centrosome amplification and aneuploidy, leading to senescence, apoptosis, and impaired proliferation in mouse embryonic fibroblasts, and microcephaly with increased perinatal lethality and shortened lifespan in mice. Importantly, both overall tumor formation in mice with constitutive, global STIL overexpression and chemical skin carcinogenesis in animals with inducible, skin-specific STIL overexpression were reduced, an effect that was not rescued by concomitant p53 inactivation. These results suggest that supernumerary centrosomes impair proliferation in vitro as well as in vivo , resulting in reduced lifespan and spontaneous as well as carcinogen-induced tumor formation.